ProCE Banner Activity

ORZORA: OS Results With Maintenance Olaparib in Platinum-Sensitive Relapsed Ovarian Cancer With a BRCA Mutation or Other HRR Mutation

Slideset Download
Conference Coverage
In the ORZORA trial, maintenance olaparib showed similar OS outcomes in patients with platinum-sensitive relapsed ovarian cancer regardless of whether patients had a germline or a somatic BRCA mutation or a non-BRCA HRR mutation.

Released: June 13, 2022

Expiration: June 12, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab